checkAd
    Startseite > Aktien > Apellis Pharmaceuticals > Nachrichten
    Apellis Pharmaceuticals Aktie
    36,90
     
    EUR
    +1,96 %
    +0,71 EUR
    Letzter Kurs 15:43:20 Tradegate
    37,80
     
    EUR
    400 STK
    Geldkurs 16:27:31
    38,09
     
    EUR
    400 STK
    Briefkurs 16:27:31
    ISIN: US03753U1060 · WKN: A2JAAW · SYM: 1JK · USA ·

    Neueste Nachrichten

    Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
    24.05.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
    14.05.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
    07.05.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
    06.05.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
    01.05.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
    26.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
    23.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    01.04.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
    11.03.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    06.03.24 · globenewswire · Apellis Pharmaceuticals
    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
    27.02.24 · globenewswire · Apellis Pharmaceuticals